Literature DB >> 15905530

Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center.

Jacqueline William1, Chad Euler, Mark J Shlomchik.   

Abstract

We used a newly validated approach to identify the initiation of an autoantibody response to identify the sites and cell differentiation pathways at early and late stages of the rheumatoid factor response. The autoimmune response is mainly comprised of rapidly turning over plasmablasts that, according to BrdU labeling, TUNEL, and hypermutation data, derive from an activated B cell precursor. Surprisingly, few long-lived plasma cells were generated. The response most likely initiates at the splenic T-B zone border and continues in the marginal sinus bridging channels. Both activated B cells and plasmablasts harbor V gene mutations; large numbers of mutations in mice with long-standing response indicate that despite the rapid turnover of responding cells, clones can persist for many weeks. These studies provide insights into the unique nature of an ongoing autoimmune response and may be a model for understanding the response to therapies such as B cell depletion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905530     DOI: 10.4049/jimmunol.174.11.6879

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  T cells that promote B-Cell maturation in systemic autoimmunity.

Authors:  Jason S Weinstein; Sairy G Hernandez; Joe Craft
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

2.  SWAP-70 deficiency causes high-affinity plasma cell generation despite impaired germinal center formation.

Authors:  Laurence Quemeneur; Veronique Angeli; Michael Chopin; Rolf Jessberger
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

3.  T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells.

Authors:  Robin A Herlands; Sean R Christensen; Rebecca A Sweet; Uri Hershberg; Mark J Shlomchik
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

Review 4.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

5.  Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo.

Authors:  Rebecca A Sweet; Michelle L Ols; Jaime L Cullen; Ashley Viehmann Milam; Hideo Yagita; Mark J Shlomchik
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 6.  Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach.

Authors:  Christopher M Tipton; Jennifer R Hom; Christopher F Fucile; Alexander F Rosenberg; Inaki Sanz
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

Review 7.  Contributions of B cells to lupus pathogenesis.

Authors:  Allison Sang; Ying-Yi Zheng; Laurence Morel
Journal:  Mol Immunol       Date:  2013-12-12       Impact factor: 4.407

8.  Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse.

Authors:  To-Ha Thai; Heide Christine Patterson; Duc-Hung Pham; Katalin Kis-Toth; Denise A Kaminski; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-26       Impact factor: 11.205

Review 9.  Dysregulation of germinal centres in autoimmune disease.

Authors:  Carola G Vinuesa; Iñaki Sanz; Matthew C Cook
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

10.  Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.

Authors:  Burkhard Möller; Daniel Aeberli; Stefan Eggli; Martin Fuhrer; Istvan Vajtai; Esther Vögelin; Hans-Rudolf Ziswiler; Clemens A Dahinden; Peter M Villiger
Journal:  Arthritis Res Ther       Date:  2009-05-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.